Hematology prior authorization at Blue Cross NC
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Blue Cross NC hematology PA at a glance
Blue Cross NC reviews hematology PA submissions against its medical policy library, with rules drawn primarily from NCCN + ASH (American Society of Hematology). Blue Cross NC-specific context: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.
Documentation packet — what to send
- Diagnosis with ICD-10 (CLL, MM, NHL, etc.)
- Stage / risk stratification
- Molecular markers (BCR-ABL, TP53, IGHV, FISH)
- Prior lines of therapy with response
- Performance status
Common denial patterns to pre-empt
Patterns observed in hematology across payers, and where Blue Cross NC's book of business overlaps:
- Off-label use (e.g., rituximab for non-Hodgkin's vs autoimmune)
- Indication-specific dosing
- Genetic testing (BCR-ABL, BRAF, TP53) not documented
- Step therapy in CLL / lymphoma
- Site of service for infusion
- Step therapy via Prime Therapeutics
Appeal angles when Blue Cross NC denies
- NCCN Compendium citation for hematologic malignancy
- Molecular / cytogenetic test results supporting indication
- Performance status documentation
- Documented response/failure of prior lines
Peer-to-peer prep
- Bring the molecular pathology report
- Quote NCCN Compendium category (1, 2A, 2B)
- Reference the pivotal trial for the prescribed regimen
- Document prior-line response (CR, PR, SD, PD) explicitly
Drug-specific PA criteria at Blue Cross NC
Deep dives on each drug's PA criteria at Blue Cross NC:
Frequently asked questions
What documentation does Blue Cross NC need for hematology prior authorizations?
Blue Cross NC's PA packet for hematology typically includes: Diagnosis with ICD-10 (CLL, MM, NHL, etc.); Stage / risk stratification; Molecular markers (BCR-ABL, TP53, IGHV, FISH); Prior lines of therapy with response. NCCN + ASH (American Society of Hematology) citations strengthen the submission.
What's the turnaround at Blue Cross NC?
Blue Cross NC standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which hematology drugs does Blue Cross NC most often PA-restrict?
Top targets in hematology: rituximab, imatinib, ibrutinib, lenalidomide, apixaban. Each follows the per-drug step therapy + documentation requirements published in Blue Cross NC's medical policy library.
How do I prep a peer-to-peer with Blue Cross NC in hematology?
Bring the molecular pathology report Quote NCCN Compendium category (1, 2A, 2B) Have the policy URL and the patient's chart open before the call.
Generate a Hematology PA packet
Open ApprovalHelp — generate a hematology PA packet tailored to Blue Cross NC's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com